alsucral 200 milligram
orion pharma a/s - sucralfate - 200 milligram
alsucral 500 milligram
orion pharma a/s - sucralfate - 500 milligram
alsucral tablets 200mg/ml milligram
orion pharma a/s - sucralfate - tablets - 200mg/ml milligram
alsucral 1
orion pharma a/s - sucralfate - 1
alsucral 1
orion pharma a/s - sucralfate - 1
alsucral
pacific pharmaceuticals limited (part of mylan) - sucralfate 0.5 g - chewable tablet - 0.5 g - active: sucralfate 0.5 g
alsucral (pacific)
pacific pharmaceuticals limited (part of mylan) - sucralfate - tablet - 0.5g, 1.0g - active: sucralfate
alsucral powder
pacific pharmaceuticals limited (part of mylan) - sucralfate 1 g - powder for oral solution - 1 g - active: sucralfate 1 g
sucralfate oral suspension
vistapharm, llc - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g in 10 ml - sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.
sucralfate- sucralfate tablet
pd-rx pharmaceuticals, inc. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g - sucralfate is indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate is contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.